| Code | CSB-RA007916MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to REGN-7508, targeting coagulation factor XI (F11), a serine protease that plays a crucial role in the intrinsic pathway of blood coagulation. Factor XI amplifies thrombin generation and contributes to fibrin clot formation, making it an important regulator of hemostasis. Elevated F11 activity has been associated with increased thrombotic risk in conditions such as venous thromboembolism, stroke, and cardiovascular disease, while F11 deficiency demonstrates reduced thrombosis without severe bleeding complications, establishing it as an attractive therapeutic target for anticoagulation strategies.
REGN-7508 (abelacimab) is a clinical-stage therapeutic antibody developed by Regeneron Pharmaceuticals that inhibits factor XIa enzymatic activity, offering potential advantages over traditional anticoagulants by separating antithrombotic effects from bleeding risk. This biosimilar antibody serves as a valuable research tool for investigating F11 biology, exploring novel anticoagulation mechanisms, studying thrombotic disorders, and supporting preclinical studies in hemostasis and cardiovascular disease research.
There are currently no reviews for this product.